| Previous Close | 82.64 |
| Open | 82.84 |
| Bid | 84.53 x 400 |
| Ask | 84.55 x 200 |
| Day's Range | 82.91 - 84.76 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 1,899,331 |
| Avg. Volume | 3,789,485 |
| Market Cap | 88.78B |
| Beta | 0.18 |
| PE Ratio (TTM) | 40.81 |
| EPS (TTM) | 2.07 |
| Earnings Date | Jul 25, 2017 |
| Dividend & Yield | 2.08 (2.51%) |
| Ex-Dividend Date | 2017-05-11 |
| 1y Target Est | 89.00 |
- The Wall Street Journal•4 minutes ago
Health-Care Stocks Get a Boost From Senate Bill Rollout
Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.
- PR Newswire•yesterday
Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego
Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain. "This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market," said David A. Ricks, Lilly's chairman, president and chief executive officer.
- Market Realist•2 days ago
Analyzing Eli Lilly’s Collaboration with KeyBioscience AG
On June 8, 2017, Eli Lilly (LLY) announced a strategic collaboration with KeyBioscience AG to focus on the development of dual amylin calcitonin receptor agonists (or DACRAs).